Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Kairos Pharma, Ltd. (KAPA) had Return on Tangible Equity of -33.12% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-1.39M |
|
-- |
|
-- |
|
$1.42M |
|
$-1.42M |
|
$0.03M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.42M |
|
$-1.18M |
|
21.42M |
|
21.42M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$3.17M |
|
-- |
|
$1.28M |
|
$4.46M |
|
$0.27M |
|
-- |
|
-- |
|
$0.27M |
|
$4.19M |
|
$4.19M |
|
$4.19M |
|
21.42M |
|
| Cash Flow Statement Financials | |
$-2.05M |
|
-- |
|
$0.18M |
|
$4.49M |
|
$2.63M |
|
$-1.86M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.05M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.12% |
|
|
Return on Tangible Equity |
-33.12% |
-31.15% |
|
-33.12% |
|
$0.20 |
|
$-0.10 |
|
$-0.10 |
|